Replies to post #794581 on NorthWest Biotherapeutics Inc (NWBO)

[10baggerz]

100% good points to keep in mind. Careful docstock or one of his aliases might deem you a "fake bull" for posting factual information that does support the AI doctor pumper 4D chess narrative 

[manibiotech]

You are exactly right

[learningcurve2020]

I’ve got to believe that Advent has picked up a few clients since that last report and revenues are more than half of what NWBO contributes. It’ll be disappointing if that’s not the case.

[dennisdave]

NW isn't going to be paying itself, hence that isn't an improvement to NW's balance sheet, though some might do a quick read and think that since NW is acquiring Advent, that cash asset will go onto NW's balance sheet. It won't; it's still only a liability to NW.

Nonsense that’s not how consolidation works. Once Advent is 100% owned, all intercompany payments vanish NWBO can’t owe money to itself. The “accounts payable” to Advent are eliminated on consolidation; only the small £1.4M + net AP owed to the former Advent owners remains. That’s minor compared to the assets, IP, and GMP infrastructure now on NWBO’s books.

And no, Advent’s past “revenues” weren’t real external sales, they were internal cost pass-throughs. By owning Advent outright, NWBO removes that entire expense stream and gains full control of manufacturing. Add in 19M shares/options cancelled, and the transaction is clearly balance-sheet accretive, not neutral. Calling that “no improvement” is just bad accounting. Nice try tough